Search

Displaying results 2321 - 2330 of 10000 in total
  1. Target

    Chemotaxis protein CheA

    go.drugbank.com/bio_entities/BE0001431
    TargetThermotoga maritima (strain ATCC 43589 / MSB8 / DSM 3109 / JCM 10099)

    CheA is autophosphorylated; it can transfer its phosphate group to either CheB or CheY (By similarity).

    Polypeptides: Chemotaxis protein CheA
  2. Drug

    Padeliporfin

    go.drugbank.com/drugs/DB15575
    ApprovedInvestigational

    [A244699] Padeliporfin was first approved by the European Commission on November 10, 2017, for the treatment of low-risk prostate cancer in adults meeting certain clinical criteria.[L39799] … It aims to destroy only cancerous lesions of the prostate, rather than ablating the entire prostate gland.

  3. Drug

    Taiwanofungus camphoratus fruiting body

    go.drugbank.com/drugs/DB19272
    Investigational

    Synonyms: Botanical agent LEAC-102
  4. Drug

    Pentaerythritol tetranitrate

    go.drugbank.com/drugs/DB06154
    ApprovedWithdrawn

    It is recognized by the FDA to be a coronary vasodilator in the treatment of heart conditions such as angina [L2395]. … It is a pentaerythritol nitrate in which all four hydroxy groups of pentaerythritol have been converted to the corresponding nitrate ester.

    Synonyms: Tetranitrato de pentaeritritilo, Tetranitrate de pentaerithrityleProducts: เพอริเตรท(R) (10 มก.)
  5. Drug

    Lorcaserin

    go.drugbank.com/drugs/DB04871
    ApprovedInvestigationalWithdrawn

    In February 2020, the FDA issued a Drug Safety Communication requesting the manufacturer of Belviq (lorcaserin hydrochloride tablets, 10 mg) and Belviq XR (lorcaserin hydrochloride extended-release tablets … , 20 mg) to voluntarily withdraw these products from the U.S. market, and the company has submitted a request to voluntarily withdraw the drug.

  6. Drug

    Carbon monoxide

    go.drugbank.com/drugs/DB11588
    ApprovedInvestigational

    The technique was first described 100 years ago, and applied to clinical practice many years after. … Since 2002, FDA has favorably reviewed three GRAS notifications for carbon monoxide use in fresh meat packaging [L2537].

    Mixtures: Co-NE-O2-N2 Mixture, Co-HE-O2-N2 Mixture
  7. Drug

    Naxitamab

    go.drugbank.com/drugs/DB15965
    ApprovedInvestigational

    [L24454] This approval requires naxitamab to be co-administered only with GM-CSF, a factor known to enhance the granulocyte-mediated antibody-dependent cytotoxicity of anti-GD2 therapies,[A224604] making … [L24929] Naxitamab-gqgk (Danyelza) was granted accelerated approval by the FDA in November 2020 for the treatment of high-risk relapsed/refractory neuroblastoma of the bone or bone marrow.

  8. Drug

    Ketobemidone

    go.drugbank.com/drugs/DB06738
    Investigational

    The most commonly cited equalisation ratio for analgesic doses is 25 mg of ketobemidone hydrobromide to 60 mg of morphine hydrochloride or sulfate and circa 8 mg of ketobemidone by injection. … It also has some NMDA-antagonist properties. This makes it useful for some types of pain that don't respond well to other opioids.

  9. Drug

    Policresulen

    go.drugbank.com/drugs/DB13492
    Investigational

    Products: ALBOTHYL VAGINAL SUPPOSITORY 90 mg
  10. Drug

    Insulin-like growth factor II

    go.drugbank.com/drugs/DB14472
    Investigational

    It is believed to be a major fetal growth factor in contrast to insulin-like growth factor I, which is a major growth factor in adults. … The insulin-like growth factor II is a well-characterized neutral peptide believed to be secreted by the liver and to circulate in the blood.

    Synonyms: CG-IGF2Products: HUCORD HSCM-100 Ampoule